![]() She participates in research projects across Africa, as well as in Asia and South America where a key interest is the support and mentoring of investigator-initiated pharmacology research projects. Key research areas involve optimising doses and drug combinations for patients with drug-resistant tuberculosis or TB/HIV co-infection, and optimising anti-tuberculosis drug use in children. MBChB(UCT), PhD in Clinical Pharmacology, Department of Medicine, University of Cape Town. His main research interests are in the therapeutic aspects of HIV-associated tuberculosis and drug-resistant tuberculosis, antiretroviral therapy in resource-limited settings, and the pharmacokinetics of antiretroviral and anti-tuberculosis drugs. MBChB, MMed, FCP SA DTM&H Head of the Division of Clinical Pharmacology Her research focuses on evaluating innovative technologies and interventions to improve the delivery of HIV/STI prevention interventions (including pre-exposure prophylaxis) and treatment in sub-Saharan Africa, especially in pregnant women, male partners and families. Honorary Senior Lecturer, School of Public Health and Family Medicine, Division of Epidemiology and Biostatistics, Desmond Tutu Health Foundation.ĭvora is an Assistant Professor of Epidemiology at the University of California, Los Angeles. Collaborations with St Mary's Hospital, London McGill University, Montreal Hvidovre Hospital, Denmark.īA, MPH, PhD (Epidemiology). Research interests: All aspects of HAART in children immune reconstitution in children TB-HIV co-infection MRSA infection primary immunodeficiency diseases. MB ChB, FCP (Paeds) (SA), BSc (Hons) Head of Paediatric Infectious Diseases, Red Cross Children's Hospital. ![]() Synthesis and structure-activity relationship studies on β-haematin inhibiting compounds. Interaction of Fe(III) haem with antimalarials and effects on haem in cultured parasites. #DREAM FALLEN VILA DO CHAVES TERROR DOWNLOAD FOR MAC FREE#Speciation and behaviour of free Fe(III) haem in aqueous solution. Biomimetic investigations of β-haematin (synthetic haemozoin/malaria pigment) formation. Research interests: understanding how the malaria parasite deals with the large influx of haem associated with ingestion and degradation of haemoglobin in its digestive vacuole and the effects of antimalarials such as chloroquine, which inhibit this process. PhD (Bioinorganic Chemistry), Head of Department and Jamison Professor of Inorganic Chemistry, Science Faculty, UCT. His work is funded by the SA MRC, SA NRF, EU FP7, EDCTP and NIH. His group’s main research interests are the study of pulmonary regulatory immunological pathways in relation to infection, rapid and field-friendly diagnosis of tuberculosis, and drug-resistant tuberculosis. He holds an honorary faculty position at UCL. Keertan Dheda (MBBCh (Wits), FCP (SA), FCCP, PhD (Lond)) is Head of the Lung Infection and Immunity Unit and Associate Professor of Respiratory Medicine (SARChI), Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town. He is the founding director of the Centre of Infectious Disease Epidemiology and Research. He has led a number of clinical epidemiology research projects in the areas of tuberculosis, HIV/Aids, immunization and STI's. Research interests: HIV cohort and infectious disease epidemiology operations research on service responses for priority health conditions data harmonisation and linkage and context-appropriate health information systems development.ĭavid is a public health specialist with many years operational experience in primary care and infectious disease service delivery. Division of Public Health Medicine and Centre for Infectious Disease Epidemiology and Research (CIDER), School of Public Health and Family Medicine Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine Health Impact Assessment directorate, Department of Health, Provincial Government of the Western Cape. ![]() Research interests range from the comprehensive evaluation of malaria treatment policy changes in southern Africa, to improving anti-malarial dosing regimens for vulnerable populations (including young children, pregnant women and those with prevalent co-morbidities, including malnutrition and HIV) and more recently leading Phase 1 clinical trials on novel antimalarial compounds. MBChB, MMed (Clinical Pharmacology) Malaria Clinical Research Group, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town. ![]() Affiliate membership is for researchers based at UCT, elsewhere than in the IDM complex, who seek supplementary membership of the IDM because their research interests align with the general focus and current activity areas of the IDM, for 3-year terms, which are renewable. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |